The Efficacy And Safety Of Once-Weekly Dulaglutide Versus Glimepiride In Patients With T2DM

Objective:To compared the efficacy and safety of once-weekly dulaglutide (1.5 mg and 0.75 mg) versus glimepiride in patients with T2DM who had inadequate glycemic control with lifestyle modifications (OAM-naive) or OAM monotherapy.Methods:After completing the screening assessments, and got through a 2-week lead-in period,eligible patients were randomly assigned in a 1:1:1 ratio to one of the three double-blind treatment arms:once-weekly dulaglutide (1.5 mg); once-weekly dulaglutide (0.75 mg); or daily glimepiride (1-3 mg/day). Two groups of different doses of dulaglutide were compared with glimepiride in the change of HbA1c,FBG,BP,BMI, lipid metabolism and safety.Result:After 26 weeks of treatment, superiority in glycemic control of dulaglutide 1.5 mg versus glimepiride and non-inferior of dulaglutide 0.75 mg versus glimepiride were statistically demonstrated in this study. Furthermore, the safety and tolerability of dulaglutide were demonstrated in this study.Conclusion:Combined with the efficacy, safety, and tolerability data, support the use of once-weekly dulaglutide as one of monotherapy options in patients with T2DM.